91 related articles for article (PubMed ID: 16027406)
1. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite.
Gustavson LE; Schweitzer SM; Koehne-Voss S; Achari R; Chira TO; Esslinger HU; Yannicelli HD
J Clin Pharmacol; 2005 Aug; 45(8):947-53. PubMed ID: 16027406
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
3. The interaction of diltiazem with lovastatin and pravastatin.
Azie NE; Brater DC; Becker PA; Jones DR; Hall SD
Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
[TBL] [Abstract][Full Text] [Related]
4. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
Kyrklund C; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2003 Jun; 73(6):538-44. PubMed ID: 12811363
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
Bergman AJ; Murphy G; Burke J; Zhao JJ; Valesky R; Liu L; Lasseter KC; He W; Prueksaritanont T; Qiu Y; Hartford A; Vega JM; Paolini JF
J Clin Pharmacol; 2004 Sep; 44(9):1054-62. PubMed ID: 15317833
[TBL] [Abstract][Full Text] [Related]
7. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
Gustavson LE; Schweitzer SM; Burt DA; Achari R; Rieser MJ; Edeki T; Chira T; Yannicelli HD; Kelly MT
Clin Ther; 2006 Mar; 28(3):373-87. PubMed ID: 16750452
[TBL] [Abstract][Full Text] [Related]
9. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
10. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
12. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson MH
Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
[TBL] [Abstract][Full Text] [Related]
13. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of pravastatin in patients on chronic hemodialysis.
Gehr TW; Sica DA; Slugg PH; Hammett JL; Raymond R; Ford NF
Eur J Clin Pharmacol; 1997; 53(2):117-21. PubMed ID: 9403282
[TBL] [Abstract][Full Text] [Related]
15. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
Jones PH; Davidson MH
Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
17. Individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects.
Ogawa K; Hasegawa S; Udaka Y; Nara K; Iwai S; Oguchi K
J Clin Pharmacol; 2003 Nov; 43(11):1268-73. PubMed ID: 14551181
[TBL] [Abstract][Full Text] [Related]
18. Development and pharmacology of fluvastatin.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
[TBL] [Abstract][Full Text] [Related]
19. Erythromycin coadministration increases plasma atorvastatin concentrations.
Siedlik PH; Olson SC; Yang BB; Stern RH
J Clin Pharmacol; 1999 May; 39(5):501-4. PubMed ID: 10234598
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.
Aberg JA; Rosenkranz SL; Fichtenbaum CJ; Alston BL; Brobst SW; Segal Y; Gerber JG;
AIDS; 2006 Mar; 20(5):725-9. PubMed ID: 16514303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]